The global rare inflammatory disease treatment market is set to experience substantial growth, according to a recent report by Future Market Insights (FMI). From a valuation of USD 13,249.2 Million in 2022, the market is projected to expand to approximately USD 17,335.8 Million by 2028, showcasing a steady compound annual growth rate (CAGR) of 4.6% during the forecast period from 2022 to 2028.
This growth trajectory reflects increased investments in research and development, alongside growing demand for diverse modes of drug administration catering to various rare inflammatory diseases. FMI’s comprehensive analysis highlights the market’s resilience in navigating evolving regulatory landscapes and underscores the imperative for innovation in orphan drug development.
Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-6428
“The global rare inflammatory disease treatment market continues to evolve amidst challenges posed by regulatory frameworks and market dynamics,” commented a FMI. “The steady growth forecasted underscores ongoing advancements in therapeutic options and the increasing focus on precision medicine approaches.”
Key factors driving market growth include advancements in therapeutic modalities, rising prevalence of rare inflammatory diseases, and the introduction of novel drug delivery methods. The market’s expansion is further supported by strategic collaborations between pharmaceutical companies and research institutions aimed at addressing unmet medical needs in rare diseases.
Key Takeaways: Rare Inflammatory Disease Treatment Market
- The market is expected to grow steadily at a CAGR of 4.6% from 2022 to 2028, reaching a value of USD 17,335.8 Million.
- North America is projected to hold the largest market share (39.9% in 2022) due to factors like well-developed healthcare and supportive reimbursement programs.
- Rising prevalence of rare diseases in the US (over 30 million affected) fuels demand for treatments.
- Increased availability of treatment options through various channels (hospitals, retail pharmacies, online) further boosts the US market.
- Europe is another significant market (24% share in 2022) driven by advancements in medical technology and new drug approvals.
- The recent extension of Nucala’s use for treating EGPA exemplifies the trend of new treatment options in Europe.
Request Customization of the Report: https://www.futuremarketinsights.com/customization-available/rep-gb-6428
Rare Inflammatory Disease Treatment Market – Competitive Landscape:
Prominent treatment providers are emphasizing on advancing drug and treatment offerings by initiating a series of clinical studies as well as forging collaborative and acquisition agreements with existing pharmaceutical companies.
- In December 2021, Pfizer Inc. announced that it had reached a definitive agreement to acquire Arena Pharmaceuticals Inc., which is developing innovative possible treatments for a variety of immuno-inflammatory diseases. The proposed acquisition offers best-in-class treatment to address unmet clinical needs for more patients with immuno-inflammatory diseases
- Likewise, in November 2021, Regeneron Pharmaceuticals Inc. announced additional positive results from a Phase 3 trial run jointly with NIAID on the use of single dose of investigational REGEN-COV® 1,200 mg sub-cutaneous injections. The findings revealed that the drug successfully protects healthy individuals from contracting COVID-19 with a success rate of 81.6%
Key Companies Profiled:
- Novartis AG
- Abbvie Inc.
- Abbott Laboratories
- Regeneron Pharmaceuticals Inc.
- Swedish Orphan Biovitrum AB
- Pfizer, Inc.
- Valeant Pharmaceutical International Inc. (Bausch Health)
- Mallinckrodt Plc.
- Johnson & Johnson
Key Segments Covered in Rare Inflammatory Disease Treatment Industry Survey:
Rare Inflammatory Disease Treatment by Indication
- RID Treatment for Ulcerative Colitis
- RID Treatment Juvenile Rheumatoid Arthritis
- RID Treatment Psoriatic Arthritis
- RID Treatment Other Indications
Rare Inflammatory Disease Treatment by Drug Class
- Biologics-based RID Treatment
- Organic Compounds-based RID Treatment
Rare Inflammatory Disease Treatment by Mode of Administration
- RID Injectables
- Oral RID Treatment
- Other RID Treatment Administration Modes
Rare Inflammatory Disease Treatment by Distribution Channel
- RID Treatment through Hospital Pharmacies
- RID Treatment through Retail Pharmacies
- RID Treatment through Online Pharmacies
Rare Inflammatory Disease Treatment Market by Region
- North America RID Treatment Market
- Latin America RID Treatment Market
- Europe RID Treatment Market
- Asia Pacific RID Treatment Market
- Middle East & Africa (MEA)
A Detailed Full Report: https://www.futuremarketinsights.com/checkout/6428
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube